Lung Toxicity in Non–Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference90 articles.
1. Cancer statistics, 2017;Siegel;CA Cancer J Clin,2017
2. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification;Travis;J Thorac Oncol,2015
3. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non–small-cell lung cancer: current knowledge and future directions;Pao;J Clin Oncol,2005
4. Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer;Kwak;N Engl J Med,2010
5. XalKori: a new paradigm of therapeutic and companion diagnostic co-development;Donnelly;Regul Rapporteur,2013
Cited by 53 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study;ESMO Open;2024-08
2. SARCOID-LIKE REACTION RELATED TO ALK-ROS INHIBITORS IN LUNG CANCER PATIENTS.;Respiratory Medicine and Research;2024-08
3. Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer;Clinical Drug Investigation;2024-07-31
4. KRASG12C Inhibitor as a Treatment Option for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia;Cancers;2024-03-28
5. Management of a Pregnant ALK-Positive Lung Cancer Patient With Alectinib-Induced Pneumonitis and Bilateral Globus Pallidus Necrosis Postpartum;Clinical Lung Cancer;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3